Please login to the form below

Not currently logged in
Email:
Password:

CCC appoints European head of social media

Chandler Chicco Companies, an inVentiv Health company, has appointed Sam Walmsley as European head of social media
Chandler Chicco Companies (CCC), an inVentiv Health company, has appointed Sam Walmsley to the newly created position as head of European social media. 

Walmsley, previously of Profero London, has led and delivered a wide range of digital projects for clients in the pharmaceutical and healthcare arena. She is set to join the European and Global teams within CCC, working on the utilisation of digital channels in pharmaceutical and healthcare communications. 

Welcoming the new appointment, Fiona Hall, European operations director said: "Increasingly our clients are keen to explore the utilisation of digital channels to communicate appropriately with stakeholders. Having Sam join the UK team and partner with our global colleagues will support us in ensuring we help our clients to optimise the use of this channel as an exciting new resource for communication." 

15th July 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics